Use of methoxymorpholino doxorubicin for the treatment of a liver tumor
Patent Information
- Application Number
- MYPI1999003920
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 1998-09-14
- Filing Date
- 1999-09-10
- Publication Date
- 2000-03-14
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for liver tumors, including primary hepatocellular carcinoma and liver metastases, are ineffective, with systemic chemotherapy offering low response rates and substantial toxicity, and there is a need for a method to achieve high drug concentrations at the hepatic tumor site while minimizing systemic exposure.
Intrahepatic administration of methoxymorpholino doxorubicin (MMDX) via the hepatic artery, potentially combined with agents like LIPIODOL®, to directly target liver tumors, reducing systemic exposure and toxicity while maintaining antitumor activity.
This approach achieves significant antitumor activity with lower doses of MMDX compared to intravenous administration, reducing systemic toxicity and improving treatment outcomes for liver tumors, as demonstrated by phase I and II studies, with notable responses in liver metastases and primary liver cancers.
Abstract
Description
Use of Metboxymorpholioo Doxorubicin for the Treatment of a Liver TumorThe present invention relates to the use of methoxymorpholinodoxorubicin for the treatment of a liver cancer; inparticular, it refers to the intrahepatic administration ofmethoxymorpholino doxorubicin for use in the liver tumortheraphy.Methoxymorpholino doxorubicin (MMDX, internal code PNTJ152243) of formulais a new doxorubicin derivative obtained with thesubstitution of the -NH2 at position 3' in the sugar moietywith a methoxymorpholino group. The compound was synthesizedin the course of a research program aimed at identifying newanthracyclines with at least partially novel modes of action,and possessing broad spectrum of activity, including activityon multidrug resistant (mdr) tumors.MMDX is active in vitro and in vivo on tumor cells resistantto anthracyclines and presenting the mdr phenotype, this lastmechanism being recognized to occur also in man.No cross-resistance was observed on tumor cells resistant toL-PAM or cDDP, or on cells resistant to Topoisomerase IIinhibitors (at-mdr).MMDX is active after i.p., i.v. or oral administration, withgood antitumor activity on murine leukemias, and on solidmurine and human tumor models.The compound differs from most anthracyc1ines in being highlypotent when administered in vivo, the optimal i.v. dose beingat least 80 fold less than that of doxorubicin. This result,and the observation that the cytotoxic activity of MMDX isincreased in vitro in the presence of mouse, rat and human11 ver microsomes, suggest that MMDX may be transformed intohighly cytotoxic metabolite(s).A well known pathway of the metabolic transformation of theanti tumor anthracyclines in mammals is the side-chaincarbonyl group reduction, giving the corresponding 13-dihydroderivative. The reduced derivative of MMDX maintains activityin vitro and in vivo against doxorubicin-resistant models, atdoses however 10 fold higher as compared to the parent drug.The high lipophilicity of the molecule, which confers to thecompound the ability to reach high intracellularconcentrations and is most likely one of the reasons of itsefficacy on resistant models, makes it effective also afteroral administration. The oral antitumor efficacy of MMDX hasbeen examined in a panel of different tumor types withvarious schedules of administration. The results demonstratethat the oral treatment with MMDX is associated, in all theanimal models examined, with an antitumor activity comparableto that observed after intravenous (i.v.) administration. Inthese models, the effective oral doses of MMDX are 1.3-2 foldhigher than the effective i.v. doses. In particular, in livermetastases from M5076 murine fibrosarcoma, the best result(doubling of survival time) was achieved with the oralformulation, administered daily for 5 days; the injectableformulation was less effective. This might be a reflection ofa different behaviour of the drug, due to first pass effectto the liver.It is well know that there is currently no effectiveconventional treatment for patient with primaryhepatocellular carcinoma (HCC) and cholangiocarcinomainvading the liver.In addition, the liver is a common site of metastasis in manyhuman cancers.Primary Liver CancerTumors of the liver are among the most common malignancies inthe world. The annual international incidence of the diseaseis approximately 1 million cases, with a male to female ratioof approximately 4:1. There are 1.2 million deaths per yearworld wide. There is a huge geographic variation incidencecorresponding to 2 / 100,000 in North America to 30 / 100,000in South East Asia, although these numbers refer often to"total liver cancer", without a differentlation betweenprimary and secondary.The highest incidence of liver cancer is seen in the Far Eastand is associated with high endemic hepatitis B carrierrates, contamination of foodstuffs, stored grains, drinkingwater and soil. Advances in the management of thesemalignancies will likely depend on immunization strategiesfor hepatitis B and C and on developing a means of decreasingcirrhosis of any origin. Cirrhosis is frequently associatedwi th HCC, especially in Europe and CJSA. Systemicchemotherapy is generally disappointing, with response rateaveraging less than 20%. Anthracyc1ines remain the mostwidely used agents. Mitomycin C is also used.A wide variety of both surgical and nonsurgical therapies havebecome available for HCC. Surgical resection and orthotopictransplantation are the only curative options, but it isestimated that less than 10% of patients are suitable for thisapproach and long-term results are poor. The lowresectability and the high recurrent rate [40% in five yearsafter surgery), together with the fact that HCC tends to befatal because of local hepatic progression rather thanwidespread metastasis, stimulated the development of severallocoregional therapeutic approaches, including intra-arteria1chemotherapy. Higher response rates appear to be reported forintra hepatic artery (IKA) chemotherapy administered alongwith embolizing agents, such as LIPIODOL™, gel foam anddegradable starch microspheres. This approach is increasinglyused in the Far East. Anthracyclines (doxorubicin andepi rubicin) are widely used in this setting. However, nosubstantial improvement in survival is obtained with currentchemotherapeutic attempts. The need for new effectivetreatments remains high.Secondary Liver CancerLiver is a common site of metastasis in many human cancersand hepatic involvement is often the major cause ofmorbidity and mortality in disseminated malignancy. Inparticular, the liver, by virtue of the portal venousdrainage system, is usually the first - and may be the only -site of metastases in many patients with primary colorectalcancer. Gastric and pancreatic cancers - but also melanoma,lung and breast cancers - may also frequently metastasize tothe liver. Metastatic liver tumors are often the firstevidence of the progression of a patient's cancer, andparticularly in colorectal cancer are the only tumorsdetected. Colorectal carcinoma is a disease of industrializednations. It is estimated that in USA over 160,000 new caseswere diagnosed yearly and that 75,000 deaths occurred as aresult of the advanced disease. Epidemiological studies showthat the incidence of colorectal carcinoma is increasing.Involvement of the liver is found in 40-70% of patients withprogressive disease and liver is the sole site of initialtumor recurrence in up to 30% of patients with metastaticdisease. Left untreated, metastatic lesions to the liver fromcolorectal cancers are associated with survival of 3 to 2 4months.For patients with isolated liver metastases, surgicalresection is the best treatment option, with 20-30% 5 yearsurvival rate. Surgery is only possible in about 10% of casesand it is extimated that up to 25% of patients undergoingsurgical resection will recur with metastatic liver cancer.Palliation with systemic chemotherapy is currently offered tomost patients with extensive or multiple liver metastases. Todate, systemic 5-fluoruracil (5-FU) plus folinic acid isconsidered the optimum treatment for metastatic colorectalcancer, yielding response rates of only 20% and overallsurvival of around 12 months. Irinotecan hydrochloridetrihydrate is the standard treatment after failure of 5-FUleucovorin, with a response rate of 15% and median survivaltime of approximately 9 months. Clinical trials are ongoingwith the objective to determine the role of irinotecan asfirst-line treatment in combination with 5-FU leucovorin.In case the disease i s conf ined to the liver and it isinoperable, regional intraarterial chemotherapy may beindicated. With the hepatic arterial infusion of 5-FU or ofits analogue, 5-fluorodeoxyuridine (FUDR) , attempts have beenmade to maximise the clinical outcome (response rate in up to50% of cases) but with no substantial effect on survival.MMDX represents a therapeutic option in the treatment of a1iver cancer.The expectation that MMDX is effective in liver neoplasmscomes from the findings of phase I and phase lb studiesconducted by intravenous route, where, out of 30 patientsevaluable for response in liver, 5 experienced regressions ofliver metastases. Two patients with colorectal cancer had a<50% regression of liver lesions after 3 cycles, two patientswith renal cancer showed a regression greater than 50% inliver lesions after 3 cycles of treatment and an additionalpatient with colorectal cancer and multiple liver metastasesat entry (subsequently dead from pulmonary embolism after thefirst cycle of treatment) showed no evidence of livermetastases at autopsy. Tumor shrinkage occurred at doses of1250 and 1500 mcg / m2 i.v.. Main toxicities were nausea andvomiting (requiring intravenous antiemetic treatment),myelosuppression and transient elevations in transaminases.In addi tion, in a phase II s tudy by i.v. rou te in breas tcancer patients with liver metastases (previously untreatedfor the advanced disease), 1 complete response, 3 partialresponses (one of them not confirmed four weeks apart) and 1minor response were observed in liver lesions of six patientstreated (at 1500 mcg / m2 i.v.).These findings suggest an interesting affinity of MMDX forliver lesions, even in tumor types resistant to conventionalchemotherapy such as colorectal cancer and renal cancer.Strong evidence of antitumor efficacy in liver is alsosupported by preclinical data. Activity of MMDX against livermetastases from M5076 murine reticulosarcoma is higher afteroral administration as compared to the i.v. route, suggestingthat a first pass effect may favour the efficacy in liver. Inaddition, MMDX administered orally is more effective on theliver metastases than on the solid primary in the same model.This specific effect on liver metastases is probably due tometabolite(s) produced by liver enzymes. This hypothesis isreinforced by several results showing MMDX being activated invitro by liver microsomes to a highly cytotoxic product. Thismetabolic conversion is believed to occur also in humans.The hints of activity observed in the current clinicalexperience, coupled with the activity of MMDX in mdr modelsand in liver metastasis models, raise the expectation of animproved clinical outcome for patients with hepaticneoplastic lesions.It would be therefore desirable to establish drug deliverystrategies to avoid the high i.v. dosages of MMDX presentlybelieved to have an antitumor activity at the hepatic leveland to improve the antitumor efficacy of MMDX against aprimary liver cancer and 1iver metastases.There is a need to achieve high MMDX concentration at thehepatic tumor site, while reducing systemic exposure andhence toxicity.The present invention fulfills such a need by providing a newmethod for administration of MMDX to a patient suffering froma liver tumor wich reduces the MMDX amount without decreasingthe MMDX's antitumor activity at the hepatic tumor site bydirectly injecting MMDX into the hepatic artery.It is therefore a first object of the present invention theuse of MMDX in the preparation of a medicament for thetreatment of a human 1iver tumor which comprises intrahepaticadministration of MMDX.It is a further obj ect of the present invent ion a method oftreating a human liver tumor which comprises the intrahepaticadministation of a therapeutically effective amount of MMDXto a patient in need thereof.It is a still further object of the present invention amethod for reducing MMDX systemic exposure of a patientsuf fering from a liver cancer which comprises theintrahepatic administration of a therapeutically effectiveamount of MMDX to said patient.According to the present invention, a 1 iver tumor can be atumor primarily confined to the liver such as, e.g. anhepatocellular carcinoma or a cholangiocarcinoma, or a livermetas tase.Preferably, the intrahepatic administration of MMDX 1 sperformed via the hepatic arthery.In a particular embodiment of the invention, MMDX isadministered via the hepatic arthery, for example, as aninfusion of from about 15 minutes to about 30 minutes every 4weeks, or as a 5-10 minute bolus every 8 weeks, to adul tpatients with either a hepatic metastatic cancer, forexampler patients with colorectal cancer who have progressedafter receiving intravenous chemotheraphy or intrahepatic 5-fluorouracil or 5-fluorodeoxyuridine (FUDR) chemotheraphy, orpatients with previously untreated primary liver carcinomasuch as, for example, hepatocellular carcinoma orcholangiocarcinoma involving the liver.In a more particular embodiment of the present invention,MMDX is administered to a patient in a dosage ranging from,e.g., about 100 mcg / m2 to about 1000 mcg / m2, preferably fromabout 100 mcg / m2 to about 800 mcg / m2, for example in a dosageof about 200 mcg / m2.In a still more particular embodiment of the presentinvention, the appropriate dose of MMDX, preferablypreviously dissolved in saline solution, is mixed with asuitable amount of an agent which remains selectively in aliver tumor after its injection through the hepatic arthery.Preferably, the amount of this agent, for example iodized oil(LIPIODOL®) , may vary from about 3 ml to about 20 ml,depending on the tumor size.LIPIODOL® is a lipid lymphographic agent which has been foundto remain selectively in 1lver tumor after its injectionthrough the hepatic arthery so it is particularly useful as acarrier of anticancer agents.The following table illustrates the suitable LIPIODOL®volumes referred to tumor size.The administration dosage of MMDX will vary depending uponthe disease status of the patient.The dosage regimen must therefore be tailored to theparticular of the patientJ s condi tions, response andassociate treatments in a manner which is conventional forany therapy, and may need to be ad jus ted in response t ochanges in conditions and / or in light of other clinicalconditions.For example, for intrahepatic therapy, freeze-dried vialscontaing 500 meg of MMDX is diluted with 5 ml of sterilesaline for injection to obtain a MMDX concentration of 100meg / ml. The appropiate dose of MMDX to be given to thepatient is optionally mixed with a suitable amount ofLIPIODOL®.The active drug can be administered directly into the lateralentry of an i.v. line inserted into the bung of anintrahepatic potacath lying beneath the upper anteriorabdominal wall. The drug can administered, for example, over30 minutes infusion in a volume of 100 ml of normal saline.Flushing of the device with 10-20 ml of saline can be done toassure that all the drug is given. Patients who do not have aportacath have a catheter inserted into the hepatic artery bya femoral Seldinger approach and the drug can be infused, forexample, over 30 minutes infusion in a volume of 100 ml ofnormal saline. The catheter is inserted under localanesthesia and can then be removed from the groin, a pressurebandage applied and nursing observations continued overnightin hospital.Object of this invention is also to provide a pharmaceuticalcomposition comprising MMDX as the active substance, inassociation with a pharmaceutically acceptable agent, asdefined above, which remains selectively in a liver tumorafter its intrahepatic injection, for example through thehepatic artery, and one or more pharmaceutically acceptableexcipients and / or carriers. The pharmaceutical compositionsare usually prepared following conventional methods and areadministered in a pharmaceutically suitable form. Forinstance, solutions for intrahepatic inj ection or infusionmay contain as a carrier, for example, sterile water orpreferably, they may be in the form of sterile aqueousisotonic saline solutions.The following Experimental Protocol illustrates but do notlimit the present invention.EXPERIMENTAL PROTOCOLA single arm, multicentre, dose-finding Phase I study of MMDX(PNU 152243) administered as a brief infusion of 30 minutesevery 4 weeks via the hepatic artery (IHA) to adult patientsei ther with hepatic metastatic colorectal cancer who haveprogressed af ter receiving intravenous chemotherapy orintrahepatic 5-fluoruracil chemotherapy, or with previouslyuntreated primary hepatocellular carcinoma orcholangiocarcinoma involving the liver was carried out. Theirdisease was confined to the liver, at the time of trialentry. Patients may have already had an intrahepat icportacath in situ or have the drug administered via thehepatic artery by a femoral Seldinger approach.The primary goal of this study was the determination ofMaximal Tolerated Dose (MTD) and Dose-Limiting Toxicities(DLTs)of MMDX when administered via the hepatic artery.Antitumor activity was documented in this study.The starting dose was 100 mcg / m2, corresponding to one thirdof the LDio in rats.On a total of 23 registered patients, 18 received intrahepatic artery (IHA) administration of MMDX.Doses tested ranged from 100 mcg / m2 to 800 mcg / m2.Results are available on 13 patients: 3 patients (6 cycles)at 100 mcg / m2, 3 patients (12 cycles) at 200mcg / m2, 3patients {4 cycles) at 400 mcg / m2, 3 patients (10 cycles) at600 mcg / m2 and 1 patient (3 cycles) at 800 mcg / m2.Hematological toxicityGrade 1 leucopenia was observed in 1 patient at 100 mcg / m2 (1cycle), 1 patient (1 cycles) at 200 mcg / m2 and 1 patient (1cycle) at 4 00 mcg / m2. AGC were however always normal. Grade1-2 thrombocytopenia occured in 1 patient (3 cycles) at 2 00mcg / m2 and in 1 patient (1 cycle) at 600 mcg / m: and wereconsidered tumor related {HCC patients). Max. grade 1 anemiawas reported in three patients at 200, 600 and 800 mcg / m2,respectively.Non-hematological toxici tyThe most frequently observed adverse events, attributable tothe study drug were nausea, vomiting and fatigue.At 100 mcg / m2: mild vomiting was reported in one out of threepatients (in 1 cycle); grade 1-2 fatigue was present in 2patients (3 cycles).At 200 mcg / m2: grade 2 nausea in 2 patients (2 cycles), grade1-2 vomi ting in 2 patients (3 eyeles) and grade 2 fatigue in1 patient (2 cycles) were reported.At 400 mcg / m2: grade 2-3 nausea occurred m 2 patients (2cycles) and grade 2 vomiting in one patient (1 cycle) . Mildlocal pain at porth-a-cath site, and mi Id alopecia werereported in one patient (1 cycLe).At 600 mcg / m2: grade 1-2 nausea in 2 patients (2 cycles),grade 2 fatigue in 1 patient (2 cycles) and mild alopecia in1 patient (2 cycles) were reported.At 800 mcg / m2: grade 1 nausea, fatigue, mucositis and feveroccurred in 1 patient (1 cycle each).No other grade 3-4 events were reported.Mild to moderate (grade 1-2) increase in transaminases(attributable to the study drug) was observed at 200 mcg / m'(2 / 3 patients), at 400 mcg / m2 (2 / 3 patients; a third patientshowed a grade 2-3 transaminase elevation probably due to theIHA technology applied) , and at 600 mcg / m^ in 2 out of 3patients. A grade 3 transaminase elevation was reported inthe patient treated at 800 mcg / m2.The maximum transaminases elevation appeared during the firstweek after treatment. Grade 2 bilirubinemia increases wereobserved starting from 100 mcg / m2, but were not considereddue to the study drug.Other severe, non tumor related, laboratory abnormalitiesconsisted of two grade 3 hyperglycemia observed in twopatients treated at 200 mcg / m2 (persisting from baseline inone diabetic patient and being post prandial in the otherpatient).ActivityTwo objective tumor response were observed in liver at 200mcg / m" in patients with HCC.One patient had measurable liver disease at study entryfollowed by NMR (overall 17.75 cm2); after 2 IHA cycles,Partial Response (PR) was achieved (reduction by more than86%) ; the PR was confirmed after the fourth IHA cycle andbecame Complete Response (CR) after the sixth IHA cycle; thepatient went off therapy and, at the moment, he is relapse-free and in follow-up.The second patient presented multiple liver lesions atbaseline (the bigger one was 6 cm diameter, evaluated byCtscan) . Also in this case, PR was observed after 2 IHAcycles and confirmed after the third IHA cycle (the biggerlesion was decreased by 50% in diameter). Despiteextrahepatic tumor progression (bone), the patient receivedanother IHA treatment after which he was withdrawn fromtherapy. Two months later liver Ctscan was repeated and theprevious findings on the bigger lesions were confirmed whilethe smallest lesions were slightly increased.In a third HCC patient treated at 800 mcg / m2, a minorresponse was reported after 3 cycles.These activity data show that the MMDX chemotherapy throughthe hepatic artery is effective for patients with livercancers at a MMDX dosage much lower than that employed byintravenous route, strongly reducincing the dangeroussystemic exposure and hence toxicity of MMDX.
Claims
5 in the preparation of a medicament formulated for intrahepatic administration via the hepatic artery in the treatment of a human liver tumor.
2. Use according to claim 1, wherein the liver tumor is a tumor primarily confined to the liver.
3. Use according to claim 2, wherein the tumor primarily confined to the liver is a 10 hepatocellular carcinoma (HCC) or a cholangiocarcinoma.
4. Use according to claim 1, wherein the tumor is a liver metastasis.
5. Use according to any of the preceeding claims, wherein MMDX is to be administered as an infusion of, from about 15 minutes to about 30 minutes , every 4 weeks.
156. Use according to any of claims 1 to 5, wherein MMDX is to be administered as a 5 - 10 minute bolus every 8 weeks.
7. Use according to any of the preceeding claims, wherein MMDX is to be administered with an agent which remains selectively in a liver tumor after its injection through the hepatic artery.
208. Use according to claim 7, wherein the agent is iodized oil.
9. Use according to any one of the preceeding claims, wherein MMDX is to be administered in a dose ranging from about 100 mcg / m2 to about 1000 mcg / m2. -1610. Use according to claim 9, wherein MMDX is to be administered in a dose ranging from about 100 mcg / m2 to about 800 mcg / m2.
11. Use according to claim 10, wherein the dose is 200 mcg / m2. 5 12. A pharmaceutical composition which comprises as an active principle MMDX and a pharmaceutically acceptable agent which is to remain selectively in a liver tumor after its injection through the hepatic artery.
13. A pharmaceutical composition according to claim 12, wherein the agent is iodized oil.10 14. Use of a pharmaceutical composition according to claim 12 or 13 for the preparation of a medicament for the treatment of a liver tumor.
15. Use of a pharmaceutical composition which comprises as an active principle MMDX and a pharmaceutically acceptable agent which remains selectively in a liver tumor after its injection through the hepatic artery, for the preparation of a medicament 15 formulated for intrahepatic administration in the treatment of a human liver tumor.
16. Use according to claim 15 wherein the agent is iodized oil.
